In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery
In vivo engineering of lymphocytes after systemic exosome-associated AAV delivery
复制标题
DOI：
10.1038/s41598-020-61518-w
复制
发表时间：
2020-03-11
影响因子：
4.6
通讯作者：
Maguire, Casey A.
中科院分区：
文献类型：
--
作者：
Breuer, Cort B.;Hanlon, Killian S.;Maguire, Casey A.
Ex-vivo gene therapy using stem cells or T cells transduced by retroviral or lentiviral vectors has shown remarkable efficacy in the treatment of immunodeficiencies and cancer. However, the process is expensive, technically challenging, and not readily scalable to large patient populations, particularly in underdeveloped parts of the world. Direct in vivo gene therapy would avoid these issues, and such approaches with adeno-associated virus (AAV) vectors have been shown to be safe and efficacious in clinical trials for diseases affecting differentiated tissues such as the liver and CNS. However, the ability to transduce lymphocytes with AAV in vivo after systemic delivery has not been carefully explored. Here, we show that both standard and exosome-associated preparations of AAV8 vectors can effectively transduce a variety of immune cell populations including CD4(+) T cells, CD8(+) T cells, B cells, macrophages, and dendritic cells after systemic delivery in mice. We provide direct evidence of T cell transduction through the detection of AAV genomes and transgene mRNA, and show that intracellular and transmembrane proteins can be expressed. These findings establish the feasibility of AAV-mediated in vivo gene delivery to immune cells which will facilitate both basic and applied research towards the goal of direct in vivo gene immunotherapies.
